Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124987 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL3404678 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL7734329 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL10340961 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL8785774 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL4071245 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL4990564 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL4080852 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL10589876 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 | |
| SCHEMBL3696828 | 1.00 | SLC2A1 (0.60) | SLC2A1CSNK1EHTR2ACA2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079665-A2 | MONOLITHIC ELECTROKINETIC PUMP FABRICATION | Waters Technologies Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008136854-A2 | MONOLITHIC ELECTROKINETIC PUMP FABRICATION | WATERS INVESTMENTS LIMITED (US) | 2008-11-13 | — | — | WO | disclosed |
| US-7008636-B2 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-10-28 | — | — | US | disclosed |
| US-6765021-B2 | ANTIDIABETIC AGENTS | WYETH | 2004-07-20 | — | — | US | disclosed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6451827-B2 | MODULATING BLOOD GLUCOSE CONCENTRATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-08-30 | — | — | US | disclosed |
| US-6214877-B1 | ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-4950414-A | MIXTURE OF POLYISOBUTENE AND PHOSPHETANE ADDITIVE | UK-MINERALOLWERKE WENZEL & WEIDMANN, GMBH (DE) | 1990-08-21 | — | — | US | disclosed |
| EP-0337355-A2 | Composition for liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4279761-A | LUBRICANT ADDITIVE | CIBA-GEIGY CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
| US-4244827-A | AS STABILIZING ADDITIVES FOR LUBRICANTS | CIBA-GEIGY CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
| US-4080307-A | AMMONIUM SALTS OF 1,3-OXA- OR 1,3-THIA-PHOSPHETANES | CIBA-GEIGY AG (CH) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | SLC2A1 39/4885CSNK1E 761/4885HTR2A 1384/4885 |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | SLC2A1 38/4885CSNK1E 761/4885HTR2A 1387/4885 |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | SLC2A1 39/4885CSNK1E 761/4885HTR2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.